Endo Health Solutions (ENDP) 8-K Jefferies 2010 Global Life Sciences Conference

ENDO PHARMACEUTICALS

Jefferies 2010 Global Life Sciences Conference

June 10, 2010

Exhibit 99.1

grow. collaborate. innovate. thrive.

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

FORWARD LOOKING STATEMENT

This

presentation

contains

forward-looking

statements

regarding,

among

other

things,

the

proposed

business

combination

between

Endo

and

HealthTronics,

Endo’s

and

HealthTronics’

financial

position,

results

of

operations,

market

position,

product

development

and

business

strategy,

as

well

as

estimates

of

Endo’s

future

total

revenues,

future

expenses,

future

net

income

and

future

earnings

per

share.

Statements

including

words

such

as

“believes,”

“expects,”

“anticipates,”

“intends,”

“estimates,”

“plan,”

“will,”

“may”

“intend,”

“guidance”

or

similar

expressions

are

forward-

looking

statements.

Because

these

statements

reflect

our

current

views,

expectations

and

beliefs

concerning

future

events,

these

forward-looking

statements

involve

risks

and

uncertainties.

Investors

should

note

that

many

factors

could

affect

the

proposed

business

combination

of

the

companies,

future

financial

results

and

could

cause

actual

results

to

differ

materially

from

those

expressed

in

forward-looking

statements

contained

in

this

presentation.

These

factors

include,

but

are

not

limited

to:

the

risk

that

the

tender

offer

and

merger

will

not

close,

the

risk

that

Endo’s

business

and/or

HealthTronics’

business

will

be

adversely

impacted

during

the

pendency

of

the

tender

offer

and

merger,

the

risk

that

the

operations

of

the

two

companies

will

not

be

integrated

successfully,

Endo’s

ability

to

successfully

develop,

commercialize

and

market

new

products;

timing

and

results

of

pre-clinical

or

clinical

trials

on

new

products;

Endo’s

ability

to

obtain

regulatory

approval

of

any

of

Endo’s

pipeline

products;

competition

for

the

business

of

Endo’s

branded

and

generic

products,

and

in

connection

with

its

acquisition

of

rights

to

intellectual

property

assets;

market

acceptance

of

our

future

products;

government

regulation

of

the

pharmaceutical

industry;

Endo’s

dependence

on

a

small

number

of

products;

Endo’s

dependence

on

outside

manufacturers

for

the

manufacture

of

a

majority

of

its

products;

Endo’s

dependence

on

third

parties

to

supply

raw

materials

and

to

provide

services

for

certain

core

aspects

of

its

business;

new

regulatory

action

or

lawsuits

relating

to

Endo’s

use

of

narcotics

in

most

of

its

core

products;

Endo’s

exposure

to

product

liability

claims

and

product

recalls

and

the

possibility

that

they

may

not

be

able

to

adequately

insure

themselves;

the

successful

efforts

of

manufacturers

of

branded

pharmaceuticals

to

use

litigation

and

legislative

and

regulatory

efforts

to

limit

the

use

of

generics

and

certain

other

products;

Endo’s

ability

to

successfully

implement

its

acquisition

and

in-licensing

strategy;

regulatory

or

other

limits

on

the

availability

of

controlled

substances

that

constitute

the

active

ingredients

of

some

of

its

products

and

products

in

development;

the

availability

of

third-party

reimbursement

for

Endo’s

products;

the

outcome

of

any

pending

or

future

litigation

or

claims

by

third

parties

or

the

government,

and

the

performance

of

indemnitors

with

respect

to

claims

for

which

Endo

has

been

indemnified;

Endo’s

dependence

on

sales

to

a

limited

number

of

large

pharmacy

chains

and

wholesale

drug

distributors

for

a

large

portion

of

its

total

revenues;

a

determination

by

a

regulatory

agency

that

Endo

is

engaging

or

has

engaged

in

inappropriate

sales

or

marketing

activities,

including

promoting

the

“off-label”

use

of

its

products,

the

risk

that

demand

for

and

acceptance

of

Endo’s

and

HealthTronics’

products

or

services

may

be

reduced;

the

risk

of

changes

in

governmental

regulations;

the

impact

of

economic

conditions;

the

impact

of

competition

and

pricing

and

other

risks

and

uncertainties,

including

those

detailed

from

time

to

time

in

the

companies’

periodic

reports

filed

with

the

Securities

and

Exchange

Commission,

including

current

reports

on

Form

8-K,

quarterly

reports

on

Form

10-Q

and

annual

reports

on

Form

10-K,

particularly

the

discussion

under

the

caption

“RISK

FACTORS"

in

their

annual

reports

on

Form

10-K

for

the

year

ended

December

31,

2009,

which

were

filed

with

the

Securities

and

Exchange

Commission.

The

forward-looking

statements

in

this

presentation

are

qualified

by

these

risk

factors.

These

are

factors

that,

individually

or

in

the

aggregate,

could

cause

our

actual

results

to

differ

materially

from

expected

and

historical

results.

The

companies’

assume

no

obligation

to

publicly

update

any

forward-looking

statements,

whether

as

a

result

of

new

information,

future

developments

or

otherwise.

2

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

FORWARD LOOKING STATEMENT CONTINUED

Additional Information

The

tender

offer

described

in

this

document

has

commenced.

Investors

and

HealthTronics

shareholders

are

strongly

advised

to

read

the

tender

offer

statement

(including an

offer

to

purchase,

letter

of

transmittal

and

related

tender

offer

documents)

and

the

related solicitation/recommendation

statement

on

Schedule 14D-9

that

will

be

filed

by

HealthTronics

with

the

SEC, because

they

will

contain important information. These

documents

will

be

available

at

no charge

on

the

SEC’s

website

at

www.sec.gov.

A

copy

of

the

solicitation/recommendation

statement

on Schedule

14D-9

may

be

obtained

free

of

charge

from

HealthTronics’

website

at

www.healthtronics.com

or

by

directing

a request

to

HealthTronics

at

9825

Spectrum

Drive, Building

3,

Austin,

Texas

78717,

Attn:

Corporate

Secretary.

In

addition,

a

copy

of

the

offer

to purchase,

letter

of

transmittal

and

certain

other

related tender

offer

documents

may

be

obtained

free

of

charge

from Endo’s

website

at

www.endo.com

or

by

directing

a

request

to

Endo

at

www.endo.com,

or

Endo

Pharmaceuticals,

100

Endo

Boulevard,

Chadds

Ford, PA

19317,

Attn:

Corporate

Secretary’s

Office.

3

grow. collaborate. innovate. thrive.

ENDO PHARMACEUTICALS

I.

Our Business

II.

Executing Strategy for Growth

III.

HealthTronics

Acquisition

IV.

Financial Outlook

4

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

STRONG OPERATING PERFORMANCE

17% 3-YEAR CAGR FOR REVENUE*

* Revenue CAGR 2006-2009.

5

Sustaining our Growth

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

STRONG CORE BUSINESS SUPPORTING GROWTH

6

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

STRONG CORE BUSINESS SUPPORTING GROWTH

Opana®

ER

Settlement with generic companies provides for 2013 entry on primary

dosage forms

Continued branded sales producing strong cash flow

Effective physician targeting and managed care strategy

Continuing strong share growth:

35% TRx growth YOY in Q1 2010

LAO market up 1% for the same period

7

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

EXECUTING THE STRATEGY

Defined parameters for expansion into adjacent therapeutic, device

and diagnostic markets that leverage our commercial infrastructure

Vantas

Axomadol

FORTEST

A

Urocidin

Jubilant

Aurigene

Supprelin LA

Valstar

LIDODERM

OPANA ER/IR

Voltaren Gel

Specialty

Generics

Percocet

FROVA

AVEED

8

Harvard

University

Impax Labs

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

DEVELOPMENT PIPELINE

Phase I

Phase II

Phase III

NDA

AVEED

TM

Long Acting Injectable

Testosterone

FORTESTA

TM

2% Testosterone Gel

Urocidin

TM

Bladder Cancer

Octreotide

Implant 

Acromegaly*   

Axomadol

Moderate to moderately severe chronic pain

Octreotide

Implant 

Carcinoid

Syndrome

Pending

Pending

* Granted orphan drug status

9

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

IMPLANT TECHNOLOGY

HYDRON®

DRUG DELIVERY TECHNOLOGY

10

IMPLANTATION

DISPERSION

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

SPECIALTY GENERICS DEVELOPMENT

11

~40 Projects

~40 Projects

25 Near-term*

25 Near-term*

13 Current

13 Current

ANDA 

ANDA 

reviews

reviews

*Near-term revenue 2010-2012

Approximately 40 projects under

development

15 Current ANDA submissions

13 with near-term launch targets

2 with long-term launch targets

Managing development for

sustainable growth

Potential efficiencies with branded

Rx business

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

12

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

Enhance Revenue Growth Through Diversification

Sustainable, long-term growth

Diversified revenue stream

Enhanced product offerings in urology

Expand Urology Business

Elevates Endo’s leadership in urology

Expands Endo’s reach and relationships with key urology practices

Increase Shareholder Value

Accretive to adjusted earnings in 2010

Diversified revenue stream beyond pharmaceuticals

Enhanced offerings in urology

13

HEALTHTRONICS –

TRANSACTION RATIONALE

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

Leading provider of urology services

Leader in lithotripsy, BPH laser and cryosurgery

Emerging urologic businesses in:

Anatomic pathology

Radiation therapy

Unique business relationship with 1/3 of urologists in U.S.

Total solution for the urology marketplace

Improve patient care

Enhance practice economics

14

HEALTHTRONICS –

CORPORATE OVERVIEW

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

TRANSACTION TERMS

HealthTronics

$223 million cash tender offer

$4.85 per share of HTRN

$0.05 accretive to adjusted diluted EPS in 2010

$0.25 dilutive to GAAP EPS in 2010

Approximately $40 million of transaction and integration costs

15

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

In exclusive negotiation to acquire company

Indicative of Endo’s ability to leverage HealthTronics

acquisition

Drug/Device approach to improve patient outcomes

Compelling clinical data

PMA approval pending

FDA Devices Panel unanimously recommended product in 2008

Strong fit with Urology business commitment

SYNERGO®

enhances current investments in bladder cancer

VALSTAR

TM

UROCIDIN

TM

MEDICAL ENTERPRISES GROUP -

POTENTIAL

TRANSACTION

16

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

ENDO’S CARE PATHWAY

17

Diagnostics

Drugs

Devices

Services

Pain

Bladder

Cancer

BPH

Prostate

Cancer

Endo with HealthTronics

will offer a full suite of products

and services as well as a direct channel to urologists

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

FINANCIAL OUTLOOK

2010 Financial Guidance

Revenue range of $1.63B -

$1.68B

Adjusted diluted EPS range of $3.20 -

$3.25

Reported (GAAP) diluted EPS range of $2.06-

$2.14

Assumes close of HealthTronics

Inc. transaction third quarter 2010

Flexible cost structure

Expect

to

generate

$300

-

$350M

in

annual

Operating

Cash

Flow

this

year

18

Endo Pharmaceuticals

grow. collaborate. innovate. thrive.

grow. collaborate. innovate. thrive.

©2010 Endo Pharmaceuticals Inc.

RECONCILIATION OF NON-GAAP MEASURES

20

For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s Current Report on Form 8-K

filed today with the Securities and Exchange Commission

Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for the Year

Ending December 31, 2010

Lower End of Range

Upper End of Range

Projected GAAP diluted income per common share

$2.06

$2.14

Upfront and milestone-related payments to partners

$0.20

$0.15

Amortization of commercial intangible assets

$0.59

$0.59

Costs incurred in connection with continued efforts to enhance the

cost structure of the Company

$0.05

$0.05

Indevus

related costs and change in fair value of contingent

consideration

$0.01

$0.01

Costs related to the acquisition of HealthTronics, Inc.

$0.41

$0.41

Interest expense adjustment for ASC 470-20 and the amortization

of the premium on debt acquired from Indevus

$0.15

$0.15

Tax effect of pre-tax adjustments at the applicable tax rates and

certain other expected cash tax savings as a result of the Indevus

and HealthTronics

acquisitions

($0.27)

($0.25)

Diluted adjusted income per common share guidance

$3.20

$3.25

The company's guidance is being issued based on certain assumptions including:

•Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results

•Includes all completed business development transactions as of March 31, 2010 and the announced acquisition of HealthTronics, Inc.